1 What is Dengue Fever (‘Breakbone Fever’)?
Dengue is a painful, viral mosquito-borne infection caused by four distinct dengue virus serotypes (DENV 1–4). It is primarily transmitted to humans through the bite of infected female Aedes aegypti and Aedes albopictus mosquitoes. Unlike malaria mosquitoes which bite primarily at night, dengue mosquitoes are aggressive daytime biters (peaking 2 hours after sunrise and several hours before sunset).
Dengue was historically dubbed “Breakbone Fever” due to the agonizing joint, muscular, and retro-orbital (behind the eyes) spasms it causes.
Typical / Mild Dengue
- Sudden high fever (up to 40°C)
- Severe headache & retro-orbital eye pain
- Crippling bone, muscle & joint ache
- Nausea, vomiting and loss of appetite
- Characteristic blotchy red skin rash
Severe Dengue (Red Flags)
Occurs as the fever breaks (days 3–7). Requires immediate emergency hospitalisation:
- Persistent vomiting & severe abdominal agony
- Bleeding gums, nosebleeds or subcutaneous bruising
- Extreme lethargy, restlessness or confusion
- Fluid accumulation / shortness of breath
- Dengue Shock Syndrome (plasma leakage)
2 Interactive Global Dengue Outbreak Tracker
Search or filter popular destinations by region for Australian travellers:
3 The Dengue Vaccine in Australia: Qdenga (TAK-003)
In Australia, the Therapeutic Goods Administration (TGA) has registered Qdenga (tetravalent dengue vaccine, live attenuated) manufactured by Takeda. The Australian Technical Advisory Group on Immunisation (ATAGI) publishes guidelines regarding who should receive this vaccine prior to travelling.
The Major Breakthrough with Qdenga vs Dengvaxia
Unlike the older dengue vaccine (Dengvaxia), which strictly required serological confirmation of a previous dengue infection prior to dosing, Qdenga can be administered to individuals regardless of prior infection history (both seronegative and seropositive individuals aged 4 years and older).
| Vaccine Aspect | ATAGI / Clinical Specification |
|---|---|
| Approved Age | Individuals aged 4 years and older |
| Schedule & Dosing | 2 doses (0.5 mL subcutaneous), given 3 months apart (0 and 3 months) |
| Vaccine Platform | Live-attenuated recombinant tetravalent (serotypes 1, 2, 3, 4) |
| Timing Before Travel | Ideally completed before departure. If travelling sooner, single-dose partial protection can be discussed with your GP. |
| Private Prescription | Available via private prescription (not funded on National Immunisation Program) |
Who Should Prioritize Qdenga Vaccination?
ATAGI specifically recommends discussing the vaccine if you fall into one of the following categories:
Absolute Contraindications (Live Vaccine)
Because Qdenga is a live-attenuated vaccine, it cannot be given to:
- Pregnant women or women planning a pregnancy within 1 month of vaccination
- Breastfeeding women
- Immunocompromised individuals (e.g., severe HIV, immunosuppressive therapy, chemotherapy, high-dose systemic steroids)
- Children under 4 years of age
Pre-Travel Dengue Risk & Vaccine Screener
Answer 4 quick questions to see your personal risk rating and tailored GP consultation guidance.
4 5-Point Mosquito Defense Checklist
Vaccination is a powerful layer of defense, but no vaccine is 100% effective against every serotype. Tick off each item below as you prepare for your trip:
5 Frequently Asked Questions by Keysborough Patients
Book Your Travel Vaccine Consultation Today
Our experienced Travel Medicine GPs provide comprehensive destination risk assessments, Qdenga dengue vaccination prescriptions, yellow fever certificates, and tailored medical kits.